A promising new development in Prader-Willi syndrome (PWS) research is underway at Bright Minds Biosciences, a biotechnology company focused on creating treatments for brain and nervous system disorders. Their latest work targets two of the most challenging symptoms of PWS: hyperphagia (an insatiable hunger) and neuropsychiatric symptoms such as anxiety, compulsive behaviours, and emotional dysregulation.
Who Are Bright Minds Biosciences?
Based in New York, Bright Minds Biosciences specialises in developing precision medicines that act on serotonin receptors — key pathways in the brain that influence mood, appetite, and behaviour. Their approach allows for highly targeted treatments that aim to be more effective and better tolerated than older medications.
Their research portfolio includes potential therapies for epilepsy, depression, and now, Prader-Willi syndrome.
What Are They Developing for PWS?
Bright Minds is developing a drug called BMB-101, designed to activate a specific serotonin receptor known as 5-HT2C. This receptor plays a central role in regulating appetite and emotional responses.
Excitingly this means:
- BMB-101 targets the brain’s hunger and behaviour circuits.
- It may help reduce constant hunger.
- It could also ease anxiety and compulsive behaviours.
This dual-action potential makes BMB-101 especially exciting, as it aims to address both physical and emotional challenges of PWS.
The drug is currently being tested in a Phase 2a clinical trial called the NOVA Study. This early-stage trial is designed to evaluate:
- How well BMB-101 works for people with PWS
- Its safety and tolerability
- The most effective dosage
The study, which is currently taking place in Adelaide, Australia, is randomised and double-blind, meaning participants are randomly assigned to receive either the drug or a placebo, and neither they nor the researchers know which they’re receiving — a standard method to ensure unbiased results.
Who’s Involved?
Bright Minds is working with leading experts in the PWS field, including:
- Dr. Jennifer Miller (University of Florida) – expert in endocrinology and PWS
- Elizabeth Roof (Vanderbilt University) – specialist in behavioural and cognitive aspects of PWS
- Dr. Theresa Strong (FPWR) – combining scientific insight with a deep understanding of family needs
- Tania Markovic (Royal Prince Alfred Hospital, Sydney) – a specialist in Metabolism and Obesity Services
Their involvement ensures the research is guided by both clinical expertise and real-world experience.
Why This Research is so Important
For families living with PWS, hyperphagia and difficulties with emotional regulation are among the most difficult daily challenges. Current treatment options are limited, and many families are searching for solutions that offer meaningful improvement in quality of life. Bright Minds’ research offers hope. By targeting the brain’s serotonin system with precision, their drug may help reduce hunger, ease anxiety, and support better emotional balance.
While it’s still early in development, the science is encouraging — and we’ll be watching closely as the trial progresses.
For more information about this study and Bright Minds Biosciences please visit www.brightmindsbio.com